The Form 4 filing, a report of an insider's stock trades, lists Eric Venker as president and Immunovant CEO. The trade took place on October 28, 2026. The filing followed on October 30, 2026.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-10-28 |
| Date of Latest Transaction | 2026-10-28 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 200,000 |
| Price | $36.59 |
| Total Transaction Value | $7,318,000.00 |
| Insider | |
| Ticker Symbol | ROIV |
| Company | Roivant Sciences Ltd. |
| Insider Name | Venker Eric |
| Insider Title | President & Immunovant CEO |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 1,199,154 |
| Position Size Change | 14.29% |
| Filing | |
| Filing Date | 2026-10-30 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a sale of ROIV shares, reported under transaction code S. The filing information lists one transaction involving 200,000 shares.
What was the average price of the transaction?
The reported average price was $36.59 per share for the sale.
How did this transaction affect the insider's holdings?
Eric Venker sold 200,000 shares and reported owning 1,199,154 shares afterward. The sale accounted for 14.29% of the shares he held before the trade.
What's the total transaction value?
The total reported transaction value was $7,318,000.00. That value covers the single sale reported for October 28, 2026.
Are there any special circumstances around this transaction?
The available transaction information identifies a Rule 10b5-1 trading-plan reference. These plans set trading instructions in advance. The reference may apply to the filing as a whole, so its scope for this sale is unclear. No footnote text was provided to confirm which transactions it covers. The available details do not establish when the plan was adopted, its trading schedule, or whether this specific sale was made under it.
For research purposes only; not investment advice.